Actym to Present Preclinical Data on Clinical Candidate ACTM-838 at 38th SITC Annual Meeting
03 Nov 2023
ImmunotherapyAACRClinical Study
BERKELEY, Calif., Nov. 3, 2023 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining the tumor-specific enrichment and payload delivery of ACTM-838 in multiple tumor models.
"Utilizing genetically modified bacteria to elicit a potent and comprehensive immune response has the potential to bring a new level of therapeutic impact to cancer patients across multiple solid tumor types," said Dr. Christopher D. Thanos, President, CEO, and Co-founder of Actym. "The data presented at this year's SITC Meeting highlights ACTM-838's ability to specifically accumulate in the tumor microenvironment and deliver two potent engineered payloads. We believe that these results further validate our scientific approach and provide a strong rationale to advance our candidate into the clinic."
ACTM-838 is a novel immunotherapy designed to locally deliver engineered IL-15 (IL-15plex) and engineered STING (eSTING) payloads to phagocytic tumor-resident myeloid cells to induce a durable anti-tumor immune response, following intravenous administration. The data that will be presented demonstrates specific uptake by tumor-resident myeloid cells in a mouse model of breast cancer, leading to the expression of IL-15plex and eSTING in the tumor microenvironment (TME), with no evidence of payload expression in other tissues. TME-specific payload delivery and efficacy was also observed in a mouse breast cancer model of metastatic disease. Actym will also show that treatment with ACTM-838 induces tumor-antigen-specific cytolytic T cells and effector T cells. Furthermore, Actym will show that in healthy human donor cells, ACTM-838 treatment results in significantly lowered inflammatory cytokines than a control strain lacking ACTM-838's genetic modifications. Patient tumor database analysis revealed numerous tumor types that have both an adenosine pathway signature for tumor-specific enrichment, and a tumor-associated myeloid cell signature for payload delivery, by ACTM-838. In addition to demonstrating compelling efficacy characteristics, intravenously administered ACTM-838 exhibits a strong safety profile in mice and non-human primates with a first-in-human clinical trial planned in Australian cancer patients in early 2024.
SITC Poster Presentation details:
Abstract number: 408
Presenter: Dr. Akshata Udyavar
Location: Ground Level - Exhibit Halls A and B1 - San Diego Convention Center
Date/Time: Saturday, November 4, 11:55 AM – 1:25 PM and 7:00 PM – 8:30 PM (PST)
About Actym
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
Contacts
Christopher Thanos, CEO
E-Mail: [email protected]
Media Requests for Actym
Dr. Alison Opalko or Sara Ortiz
Trophic Communications
Phone: +49 151 54041130 or +49 170 3222493
E-Mail: [email protected]
SOURCE Actym Therapeutics, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.